NCT00045292View on ClinicalTrials.gov

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2002

Study Completion Date

October 31, 2004

Conditions
Cancer
Interventions
DRUG

acyclovir

DRUG

acyclovir sodium

DRUG

valacyclovir

Trial Locations (6)

75246

Baylor University Medical Center, Dallas

84132

Huntsman Cancer Institute, Salt Lake City

94305

Stanford Cancer Center at Stanford University Medical Center, Stanford

91010-3000

City of Hope Comprehensive Cancer Center, Duarte

68198-3330

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00045292 - Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation | Biotech Hunter | Biotech Hunter